A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer

Sameer Sharma, Feng Qian, Bernadette Keitz, Deborah Driscoll, Mathew J. Scanlan, Jonathan Skipper, Kerry J Rodabaugh, Shashikant Lele, Lloyd J. Old, Kunle Odunsi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives. Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics. Methods. One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed. Results. AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012). Conclusions. Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalGynecologic Oncology
Volume99
Issue number1
DOIs
StatePublished - Oct 1 2005

Fingerprint

Protein Kinases
Messenger RNA
Survival
Testicular Neoplasms
Antigens
Ovarian Neoplasms
Ovarian epithelial cancer
Testis
Multivariate Analysis
Active Immunotherapy
Neoplasms
Polymerase Chain Reaction
Residual Neoplasm
Immunotherapy
RNA
Recurrence
Drug Therapy
Cell Line

Keywords

  • AKAP-3
  • Cancer-testis antigen
  • Immunotherapy
  • Ovarian cancer
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Sharma, S., Qian, F., Keitz, B., Driscoll, D., Scanlan, M. J., Skipper, J., ... Odunsi, K. (2005). A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecologic Oncology, 99(1), 183-188. https://doi.org/10.1016/j.ygyno.2005.06.006

A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. / Sharma, Sameer; Qian, Feng; Keitz, Bernadette; Driscoll, Deborah; Scanlan, Mathew J.; Skipper, Jonathan; Rodabaugh, Kerry J; Lele, Shashikant; Old, Lloyd J.; Odunsi, Kunle.

In: Gynecologic Oncology, Vol. 99, No. 1, 01.10.2005, p. 183-188.

Research output: Contribution to journalArticle

Sharma, S, Qian, F, Keitz, B, Driscoll, D, Scanlan, MJ, Skipper, J, Rodabaugh, KJ, Lele, S, Old, LJ & Odunsi, K 2005, 'A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer', Gynecologic Oncology, vol. 99, no. 1, pp. 183-188. https://doi.org/10.1016/j.ygyno.2005.06.006
Sharma, Sameer ; Qian, Feng ; Keitz, Bernadette ; Driscoll, Deborah ; Scanlan, Mathew J. ; Skipper, Jonathan ; Rodabaugh, Kerry J ; Lele, Shashikant ; Old, Lloyd J. ; Odunsi, Kunle. / A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. In: Gynecologic Oncology. 2005 ; Vol. 99, No. 1. pp. 183-188.
@article{43735d6501c34d949d8c55a3b79a894b,
title = "A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer",
abstract = "Objectives. Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics. Methods. One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed. Results. AKAP-3 mRNA expression was demonstrated in 43/74 (58{\%}) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012). Conclusions. Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.",
keywords = "AKAP-3, Cancer-testis antigen, Immunotherapy, Ovarian cancer, Prognosis",
author = "Sameer Sharma and Feng Qian and Bernadette Keitz and Deborah Driscoll and Scanlan, {Mathew J.} and Jonathan Skipper and Rodabaugh, {Kerry J} and Shashikant Lele and Old, {Lloyd J.} and Kunle Odunsi",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.ygyno.2005.06.006",
language = "English (US)",
volume = "99",
pages = "183--188",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer

AU - Sharma, Sameer

AU - Qian, Feng

AU - Keitz, Bernadette

AU - Driscoll, Deborah

AU - Scanlan, Mathew J.

AU - Skipper, Jonathan

AU - Rodabaugh, Kerry J

AU - Lele, Shashikant

AU - Old, Lloyd J.

AU - Odunsi, Kunle

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Objectives. Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics. Methods. One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed. Results. AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012). Conclusions. Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.

AB - Objectives. Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics. Methods. One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed. Results. AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012). Conclusions. Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.

KW - AKAP-3

KW - Cancer-testis antigen

KW - Immunotherapy

KW - Ovarian cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=25144524979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144524979&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.06.006

DO - 10.1016/j.ygyno.2005.06.006

M3 - Article

VL - 99

SP - 183

EP - 188

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -